Circular Genomics

Are you looking to enhance the standard of care for patients diagnosed with Major Depressive Disorder (MDD)? Discover how MindLight can revolutionize treatment by identifying which patients may benefit from therapies beyond SSRIs. MindLight's innovative approach helps identify personalized treatment plans, ensuring your patients receive the most effective care tailored to their needs. Watch this video to learn more about how MindLight can transform your practice and improve patient outcomes: https://hubs.la/Q03fFXfM0

Navigating the complexities of #MajorDepressiveDisorder (MDD) treatment can be daunting, especially when it comes to predicting patient responses to SSRIs. The MindLight Antidepressant Response Test™ revolutionizes psychiatric care by offering precise predictions on SSRI effectiveness, allowing for faster and more tailored treatment plans. Join us for an insightful on-demand webinar with Nikolaos Mellios, MD, PhD, Chief Scientific Officer at Circular Genomics. Discover how MindLight can enhance your approach to depression treatment and improve patient outcomes. 🔗 Register for the Webinar: https://hubs.la/Q03fkWns0

Happy #NewMemberMonday!   👩🔬 Ascendis Pharma leverages its technology to create therapies in endocrinology and oncology 🥼 Circular Genomics specializes in precision psychiatric and neurologic medicine ✨ Decibel Bio is revolutionizing plant biotechnology with the first crop epigenetic platform 🔬 Eurofins CDMO Alphora provides clients with API and drug product development services 🧪 Mesa Laboratories, Inc. manufactures life science tools and quality control products 👨🔬 Snow Canyon Therapeutics develops therapies for neurodegenerative diseases

Today, we raise awareness about #BipolarDisorder, a condition that affects approximately 2.6% of adults (around 5.7 million people) in the United States. Let's break the stigma and support those living with bipolar disorder. For more information and resources, visit the American Psychiatric Association's page: https://lnkd.in/eQYvSgQ2

In this week's San Diego Newsletter: Circular Genomics joins Lilly Gateway Labs to develop its RNA platform for Alzheimer’s; Dexcom survey shows healthcare providers opt for CGM tech over new meds in diabetes; Scripps Health plans to build a $1.2B med center in San Marcos; and more. Subscribe: https://bit.ly/4iqn5b1

For healthcare providers treating patients with #MajorDepressiveDisorder (MDD), identifying which patients may respond to SSRIs can be challenging. The MindLight Antidepressant Response Test™ offers an innovative approach to personalized psychiatric care by predicting the likelihood of response to #SSRI antidepressants. This enables you to deliver quicker, more personalized treatment plans to meet each patient's specific needs. Watch our on-demand webinar featuring Nikolaos Mellios, MD, PhD, the Chief Scientific Officer at Circular Genomics, to learn more about how MindLight can transform your approach to depression treatment. Sign up now and elevate your patient care! 🔗 Sign Up for the Webinar: https://hubs.la/Q03dqq6J0

Identifying the right treatment for patients diagnosed with #MajorDepressiveDisorder (MDD) can be incredibly challenging. The trial and error process of finding the most effective treatment can be time-consuming and frustrating for both patients and healthcare providers. The MindLight Antidepressant Response Test™ can help healthcare providers stratify MDD patients according to their likelihood to respond to SSRIs. This innovative test based on brain-derived biomarkers can identify which patients may benefit from alternative treatment methods, potentially saving valuable time and improving patient outcomes.

We are excited to announce that our CEO, Paul Sargeant, PhD recently presented at the LSI USA Emerging MedTech Summit! Paul's insightful presentation showcased Circular Genomics' cutting-edge approaches and pioneering advancements in the medtech industry. His participation underscores our unwavering commitment to driving progress in precision psychiatry. #MedTech #Innovation #Healthcare #LSIUSA25

Circular Genomics shared that it will relocate its headquarters to Eli Lilly and Company's Gateway Labs innovation hub in San Diego, California. https://lnkd.in/dfRchuhb #biotechnology #clinicalresearch #corporateaffairs #diagnostics #healthtech #pharmaceuticals

SDBN Feed: Circular Genomics Strengthens Scientific Advisory Board with Addition of Alzheimer’s Disease Expert https://lnkd.in/gg8Tg4T4 Phyllis Barkman Ferrell, MBA, DrPH, brings decades of experience in neurological conditions with a focus on Alzheimer’s disease SAN DIEGO, March 19, 2025 /PRNewswire/ — Circular Genomics, a global leader in circular RNA (circRNA) biomarkers [...]